Critical Comparison: Tauriga Sciences (OTCMKTS:TAUG) & Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) and Tauriga Sciences (OTCMKTS:TAUG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Valuation and Earnings

This table compares Icon and Tauriga Sciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.28 billion	1.98	$791.47 million	$7.39	27.46
Tauriga Sciences	N/A	N/A	N/A	N/A	N/A

Icon has higher revenue and earnings than Tauriga Sciences.

Insider & Institutional Ownership

95.6% of Icon shares are held by institutional investors. 44.0% of Icon shares are held by company insiders. Comparatively, 3.5% of Tauriga Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Icon and Tauriga Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	0	11	9	2	2.59
Tauriga Sciences	0	0	0	0	0.00

Icon presently has a consensus price target of $205.31, indicating a potential upside of 1.18%. Given Icon’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Icon is more favorable than Tauriga Sciences.

Profitability

This table compares Icon and Tauriga Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Icon	7.40%	10.58%	6.01%
Tauriga Sciences	N/A	N/A	N/A

Summary

Icon beats Tauriga Sciences on 10 of the 10 factors compared between the two stocks.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

About Tauriga Sciences

Tauriga Sciences, Inc. produces and sells cannabidiol infused chewing gum under the Tauri-Gum brand name. It also develops anti-nausea products; and skin care products include CBD facemasks; CBD daily moisturizer; CBD anti-wrinkle dream, hand, and foot cream with hemp seed oil; CBD massage and body oil; CBD body revive roll-on; CBD transdermal patch; and CBD body spray. In addition, the company offers rainbow deluxe sampler pack, CBD non-GMO dietary supplements, and CBD scented bath bombs. It sells its products through e-commerce, distributors, and wholesale channels. The company has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 (novel coronavirus) test. Tauriga Sciences, Inc. was founded in 2001 and is headquartered in Wappingers Falls, New York.